ストックスクリーナーアプリを入手
1.95
0.52%
0.01
プレマーケット:
1.93
-0.02
-1.03%
前日終値:
$1.94
開ける：
$1.95
24時間の取引高:
7.59M
Relative Volume:
1.25
時価総額：
$351.17M
収益：
$850.00K
当期純損益:
$-66.49M
株価収益率:
-4.4972
EPS:
-0.4336
ネットキャッシュフロー:
$-49.17M
1週間 パフォーマンス:
+5.98%
1か月 パフォーマンス:
-64.22%
6か月 パフォーマンス:
-48.95%
1年 パフォーマンス:
+4.84%
1日の値動き範囲:
$1.8416
$2.00
1週間の範囲:
$1.64
$2.02
52週間の値動き範囲:
$1.61
$6.88
Compass Therapeutics Inc Stock (CMPX) Company Profile
Compare CMPX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
1.95 | 349.37M | 850.00K | -66.49M | -49.17M | -0.4336 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-13 | 開始されました | Craig Hallum | Buy |
| 2026-01-05 | 開始されました | William Blair | Outperform |
| 2025-12-03 | 開始されました | Canaccord Genuity | Buy |
| 2025-12-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-12-03 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-07-01 | 再開されました | Raymond James | Outperform |
| 2025-04-02 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 開始されました | Guggenheim | Buy |
| 2025-02-19 | 開始されました | Piper Sandler | Overweight |
| 2024-12-23 | 開始されました | D. Boral Capital | Buy |
| 2024-11-15 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 開始されました | Jefferies | Buy |
| 2023-01-27 | 開始されました | Stifel | Buy |
| 2022-05-23 | 再開されました | H.C. Wainwright | Buy |
| 2022-03-15 | 開始されました | Ladenburg Thalmann | Buy |
| 2022-01-19 | 開始されました | B. Riley Securities | Buy |
| 2021-12-22 | 開始されました | Raymond James | Outperform |
| 2021-12-20 | 開始されました | SVB Leerink | Outperform |
| 2021-12-15 | 開始されました | Wedbush | Outperform |
すべてを表示
Compass Therapeutics Inc (CMPX) 最新ニュース
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update - Investing News Network
Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX) - Yahoo Finance
Compass Therapeutics, Inc. 1Q 2026: Revenue ($18.76M), EPS ($0.1) — 10-Q Summary - TradingView
CMPX: Q1 2026 net loss rose to $18.3M; tovecimig advanced with positive BTC data and FDA orphan status - TradingView
Compass Therapeutics Q1 net loss widens on higher R&D, G&A costs - TradingView
CMPX: Tovecimig achieved key clinical milestones in BTC, with strong cash reserves supporting future trials - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Therapeutics, Inc. (CMPX) And Encourages Stockholders to Connect - ACCESS Newswire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
symbol__ Stock Quote Price and Forecast - CNN
LifeSci Capital Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
CMPX Stock Plunges As Traders Weigh Cancer Trial Fallout - StocksToTrade
CMPX Forecast, Price Target & Analyst Ratings | COMPASS THERAPEUTICS INC (NASDAQ:CMPX) - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc.CMPX - PR Newswire
Compass Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Compass Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Anderman Jonathanmoomoo - Moomoo
Compass Therapeutics | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer Lerner Neilmoomoo - Moomoo
Compass Therapeutics | DEFA14A: Others - Moomoo
Compass Therapeutics general counsel Jonathan Anderman buys $47,250 in stock - Investing.com India
Compass Therapeutics chief accounting officer buys $28,350 in stock - Investing.com UK
Compass Therapeutics chief accounting officer buys $28,350 in stock By Investing.com - Investing.com India
Compass Therapeutics (NASDAQ: CMPX) CAO buys 15,000 shares - Stock Titan
Compass Therapeutics (CMPX) general counsel buys more company stock - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Compass Therapeutics, Inc. (CMPX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Compass Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Lerner Neil - Moomoo
CMPX Stock Has Retail Buzzing Ahead Of High-Stakes Cancer Drug Trial Update - Stocktwits
Compass Therapeutics (CMPX) CAO receives 15,000-share equity grant - Stock Titan
CMPX Stock Sinks As Trial Failure Hammers Compass Therapeutics - StocksToTrade
CMPX Stock Plunges As Trial Failure Triggers Downgrade And Probe - StocksToTrade
Compass Therapeutics | DEF 14A: Definitive information statements - Moomoo
[DEF 14A] Compass Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re‑Rating Opportunity? - Yahoo Finance
Compass Therapeutics’s stock crashes after OS miss in BTC trial - MSN
[ARS] Compass Therapeutics, Inc. SEC Filing - Stock Titan
Compass Therapeutics (CMPX) Is Down 65.4% After Tovecimig Combo Meets Key BTC Trial EndpointsWhat's Changed - Sahm
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Crude Oil Gains Over 1%; Verizon Posts Upbeat Earnings - Sahm
US Stocks Mixed; Nasdaq Falls Over 100 Points - Sahm
Citizens Jmp Reiterates Market Outperform Rating for Compass Therapeutics (NASDAQ:CMPX) - MarketBeat
A Quick Look at Today's Ratings for Compass Therapeutics(CMPX.US), With a Forecast Between $6 to $24 - Moomoo
Raymond James Downgrades Compass Therapeutics to Market Perform From Outperform - marketscreener.com
Raymond James downgrades Compass Therapeutics stock rating on trial results - Investing.com Canada
ABL Bio Partner Compass to Pursue FDA Approval Despite Missed Survival Endpoint - Seoul Economic Daily
CMPX - Finviz
Compass drug shows mixed late-stage results, shares slide - The Pharma Letter
Compass Therapeutics stock rating maintained at outperform by Citizens - Investing.com
Compass Therapeutics Inc (CMPX) Stock Price, Quote, News & History - Benzinga
Compass Therapeutics (NASDAQ:CMPX) Hits New 12-Month LowWhat's Next? - MarketBeat
ABL Bio Partner Compass Meets PFS Endpoint in Bile Duct Cancer Trial - Seoul Economic Daily
Compass Therapeutics boosts PFS in biliary cancer, eyes FDA BLACHOSUNBIZ - Chosunbiz
Compass Therapeutics-Aktie: 64 Prozent weg, weil Statistik zickt! - Finanztrends
Compass Therapeutics Inc (CMPX) 財務データ
収益
当期純利益
現金流量
EPS
0.14%
0.48%
大文字化:
|
ボリューム (24 時間):